巴瑞替尼可用于治疗重度斑秃

Alopecia areata is an autoimmune disease characterized by rapid loss of hair, eyebrows and eyelashes. The global incidence rate is approximately 2%. Most patients with alopecia areata are relatively young, with up to 66% of patients younger than 30 years old. People with alopecia areata have an increased overall risk of developing other autoimmune diseases. It is the first targeted drug approved by the FDA for systemic therapy for alopecia areata. Baricitinib is a Janus kinase (JAK) inhibitor. JAK is an intracellular enzyme that transmits signals through the interaction of cytokines or growth factor-receptors on the cell membrane, thereby affecting hematopoietic and immune cell functions.

Baricitinib can be used to treat severe alopecia areata

Baricitinib (trade name: OlumiantR) is an oral small molecule JAK inhibitor jointly developed by Eli Lilly and Incyte. On June 13, 2022, baricitinib was approved by the FDA for priority review and marketed for the treatment of severe alopecia areata in adult patients, and received breakthrough therapy designation. This is the first time the FDA has approved a systemic treatment for alopecia areata (i.e., treating the entire body rather than a specific area).

The effect of baricitinib in the treatment of severe alopecia areata

Research purpose: To explore the clinical efficacy and safety of baricitinib in the treatment of patients with alopecia areata [1].

Research methods: 58 patients with alopecia areata were divided into a reference group and an observation group according to the random number table method, with 29 cases in each group. The reference group was treated with conventional drugs, and the observation group was treated with baricitinib on the basis of the reference group. The treatment effects, occurrence of adverse reactions, and quality of life scores before and after treatment were compared between the two groups.

Research results: The total effective rate of treatment in the observation group was 96.55%, which was higher than 72.41% in the reference group, and the difference was statistically significant (P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (P>0.05). After treatment, the material life, physical function, social function, and psychological function scores of the observation group were (92.74±2.18), (92.64±2.53), (91.67±2.18), and (91.65±2.53) points respectively, which were all higher than those of the reference group (82.64±2.53). 2.57), (86.21±3.03), (85.67±2.57), (82.67±2.03) points, the differences were all statistically significant (P<0.05).

Research conclusion: The clinical efficacy of baricitinib in the treatment of patients with alopecia areata is accurate and safe. It has a good effect on improving the quality of life of patients and is worthy of clinical promotion and application.

References

[1] Wang Xiaohong. Analysis of the efficacy and safety of baricitinib in the treatment of alopecia areata [J]. Chinese Practical Medicine, 2022, 17(26): 129-131. DOI: 10.14163/j.cnki.11-5547/r.2022.26.035.

Recommended hot articles: